FDA reminds investors about the risks of advisory panels

July 28, 2026 03:08 PM EDT PharmaFDA+ FDA re­minds in­vestors that re-eval­u­a­tions don’t equal new con­clu­sions. Just ask Capri­cor and Replimune Max Bayer Senior Reporter Two days, two sim­i­lar brief­ing doc­u­ments and two com­pa­nies with div­ing share prices. The FDA this week laid out its con­cerns with clin­i­cal da­ta from … Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER